BR112021000331A2 - Derivados de fenil-n-quinolina para tratamento de uma infecção por vírus de rna - Google Patents
Derivados de fenil-n-quinolina para tratamento de uma infecção por vírus de rna Download PDFInfo
- Publication number
- BR112021000331A2 BR112021000331A2 BR112021000331-2A BR112021000331A BR112021000331A2 BR 112021000331 A2 BR112021000331 A2 BR 112021000331A2 BR 112021000331 A BR112021000331 A BR 112021000331A BR 112021000331 A2 BR112021000331 A2 BR 112021000331A2
- Authority
- BR
- Brazil
- Prior art keywords
- group
- compound
- formula
- alkyl group
- optionally substituted
- Prior art date
Links
- 208000009341 RNA Virus Infections Diseases 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims abstract description 198
- 150000003839 salts Chemical class 0.000 claims abstract description 70
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 64
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 62
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 60
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 55
- 238000011282 treatment Methods 0.000 claims abstract description 54
- 230000002265 prevention Effects 0.000 claims abstract description 45
- 125000005843 halogen group Chemical group 0.000 claims abstract description 40
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 29
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 18
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 17
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000000460 chlorine Substances 0.000 claims description 167
- 208000036142 Viral infection Diseases 0.000 claims description 158
- 230000009385 viral infection Effects 0.000 claims description 158
- 241001493065 dsRNA viruses Species 0.000 claims description 97
- 201000009182 Chikungunya Diseases 0.000 claims description 55
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 50
- 206010012310 Dengue fever Diseases 0.000 claims description 48
- 208000025729 dengue disease Diseases 0.000 claims description 48
- 208000001490 Dengue Diseases 0.000 claims description 47
- 229910052731 fluorine Inorganic materials 0.000 claims description 37
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 36
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 21
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 125000004076 pyridyl group Chemical group 0.000 claims description 19
- 229910003827 NRaRb Inorganic materials 0.000 claims description 18
- 229910006069 SO3H Inorganic materials 0.000 claims description 18
- 206010022000 influenza Diseases 0.000 claims description 18
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 15
- -1 format Chemical compound 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 8
- 150000007529 inorganic bases Chemical class 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 229910052744 lithium Inorganic materials 0.000 claims description 7
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000002524 organometallic group Chemical group 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 3
- 229940072107 ascorbate Drugs 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 229910000831 Steel Inorganic materials 0.000 abstract 1
- 239000010959 steel Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 192
- 241000700605 Viruses Species 0.000 description 63
- 241000725643 Respiratory syncytial virus Species 0.000 description 59
- 208000015181 infectious disease Diseases 0.000 description 59
- 239000011541 reaction mixture Substances 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 50
- 230000002829 reductive effect Effects 0.000 description 49
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 36
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 22
- 235000019341 magnesium sulphate Nutrition 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 241001502567 Chikungunya virus Species 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 16
- 229910052786 argon Inorganic materials 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000012512 characterization method Methods 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 239000012267 brine Substances 0.000 description 12
- 229910000024 caesium carbonate Inorganic materials 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 235000015320 potassium carbonate Nutrition 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 239000012300 argon atmosphere Substances 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 206010022005 Influenza viral infections Diseases 0.000 description 8
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000711504 Paramyxoviridae Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000011261 inert gas Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- VAXOCTXTVIVOQE-UHFFFAOYSA-N 2,8-dichloroquinoline Chemical compound C1=CC=C(Cl)C2=NC(Cl)=CC=C21 VAXOCTXTVIVOQE-UHFFFAOYSA-N 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 241000711513 Mononegavirales Species 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 241000114864 ssRNA viruses Species 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 5
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 5
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 5
- 235000019798 tripotassium phosphate Nutrition 0.000 description 5
- 241000710929 Alphavirus Species 0.000 description 4
- 241000255925 Diptera Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000710924 Togaviridae Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- HEZQDPPKEJUAIA-UHFFFAOYSA-N 8-chloro-N-(2-cyclopropyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC(C)C)C1CC1 HEZQDPPKEJUAIA-UHFFFAOYSA-N 0.000 description 3
- SLARZWOSEIWSQU-UHFFFAOYSA-N 8-chloro-N-(4-cyclobutyloxy-2-methylphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC1CCC1)C SLARZWOSEIWSQU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000710781 Flaviviridae Species 0.000 description 3
- 241000711920 Human orthopneumovirus Species 0.000 description 3
- OPRYEICDOHDFSZ-UHFFFAOYSA-N N-[2-cyclopropyl-4-(2-fluorophenoxy)phenyl]quinolin-2-amine Chemical compound C1(CC1)C1=C(C=CC(=C1)OC1=C(C=CC=C1)F)NC1=NC2=CC=CC=C2C=C1 OPRYEICDOHDFSZ-UHFFFAOYSA-N 0.000 description 3
- ZLKJRTMCCWGIOD-UHFFFAOYSA-N N-[4-(2-fluorophenoxy)-2-methylphenyl]quinolin-2-amine Chemical compound FC1=C(OC2=CC(=C(C=C2)NC2=NC3=CC=CC=C3C=C2)C)C=CC=C1 ZLKJRTMCCWGIOD-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 239000003586 protic polar solvent Substances 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 2
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical class [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 2
- DYABZSCHQLKCLT-UHFFFAOYSA-N 2-bromo-1-nitro-4-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=C([N+]([O-])=O)C(Br)=C1 DYABZSCHQLKCLT-UHFFFAOYSA-N 0.000 description 2
- ZGWYJWDUDUADBZ-UHFFFAOYSA-N 2-bromo-4-(2-fluorophenoxy)-1-nitrobenzene Chemical compound BrC1=C(C=CC(=C1)OC1=C(C=CC=C1)F)[N+](=O)[O-] ZGWYJWDUDUADBZ-UHFFFAOYSA-N 0.000 description 2
- ROSTYHNIIDIBEG-UHFFFAOYSA-N 2-bromo-4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1Br ROSTYHNIIDIBEG-UHFFFAOYSA-N 0.000 description 2
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 2
- VIDAXNKOHNIIKH-UHFFFAOYSA-N 2-cyclopropyl-1-nitro-4-propan-2-yloxybenzene Chemical compound C1(CC1)C1=C(C=CC(=C1)OC(C)C)[N+](=O)[O-] VIDAXNKOHNIIKH-UHFFFAOYSA-N 0.000 description 2
- JISAWEROFDRHAV-UHFFFAOYSA-N 2-cyclopropyl-4-(2-fluorophenoxy)-1-nitrobenzene Chemical compound C1(CC1)C1=C(C=CC(=C1)OC1=C(C=CC=C1)F)[N+](=O)[O-] JISAWEROFDRHAV-UHFFFAOYSA-N 0.000 description 2
- WSTJYYXJWXJSKO-UHFFFAOYSA-N 2-cyclopropyl-4-(2-fluorophenoxy)aniline Chemical compound C1(CC1)C1=C(N)C=CC(=C1)OC1=C(C=CC=C1)F WSTJYYXJWXJSKO-UHFFFAOYSA-N 0.000 description 2
- ZUNPMKJMQIISMK-UHFFFAOYSA-N 2-cyclopropyl-4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1C1CC1 ZUNPMKJMQIISMK-UHFFFAOYSA-N 0.000 description 2
- HSJUILMBFMGXKM-UHFFFAOYSA-N 2-cyclopropyl-4-propan-2-yloxyaniline Chemical compound C1(CC1)C1=C(N)C=CC(=C1)OC(C)C HSJUILMBFMGXKM-UHFFFAOYSA-N 0.000 description 2
- CNBGSGDQBJKWJQ-UHFFFAOYSA-N 2-ethyl-4-(trifluoromethoxy)aniline Chemical compound CCc1cc(OC(F)(F)F)ccc1N CNBGSGDQBJKWJQ-UHFFFAOYSA-N 0.000 description 2
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 2
- YVUIYMSXNNADGT-UHFFFAOYSA-N 4-(2-fluorophenoxy)-2-methyl-1-nitrobenzene Chemical compound C1=C([N+]([O-])=O)C(C)=CC(OC=2C(=CC=CC=2)F)=C1 YVUIYMSXNNADGT-UHFFFAOYSA-N 0.000 description 2
- GFGWIIFHXQFNOT-UHFFFAOYSA-N 4-(2-fluorophenoxy)-2-methylaniline Chemical compound C1=C(N)C(C)=CC(OC=2C(=CC=CC=2)F)=C1 GFGWIIFHXQFNOT-UHFFFAOYSA-N 0.000 description 2
- XBVKHCYATIFLLC-UHFFFAOYSA-N 4-cyclobutyloxy-2-methyl-1-nitrobenzene Chemical compound C1(CCC1)OC1=CC(=C(C=C1)[N+](=O)[O-])C XBVKHCYATIFLLC-UHFFFAOYSA-N 0.000 description 2
- KRLUYHWGZIXOCF-UHFFFAOYSA-N 4-cyclobutyloxy-2-methylaniline Chemical compound C1=C(N)C(C)=CC(OC2CCC2)=C1 KRLUYHWGZIXOCF-UHFFFAOYSA-N 0.000 description 2
- PNSILPMFOLLCPY-UHFFFAOYSA-N 4-cyclopentyloxy-2-methylaniline Chemical compound C1=C(N)C(C)=CC(OC2CCCC2)=C1 PNSILPMFOLLCPY-UHFFFAOYSA-N 0.000 description 2
- PIIZYNQECPTVEO-UHFFFAOYSA-N 4-nitro-m-cresol Chemical compound CC1=CC(O)=CC=C1[N+]([O-])=O PIIZYNQECPTVEO-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical class OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IGIUATXARLJAIG-UHFFFAOYSA-N 8-chloro-N-[2-cyclopropyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC(F)(F)F)C1CC1 IGIUATXARLJAIG-UHFFFAOYSA-N 0.000 description 2
- UACXLWKZUWDESL-UHFFFAOYSA-N 8-chloro-N-[2-ethyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC(F)(F)F)CC UACXLWKZUWDESL-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 241000710815 Dengue virus 2 Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 206010054261 Flavivirus infection Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001661732 Isavirus Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000711931 Rhabdoviridae Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000013100 final test Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- IRZRJANZDIOOIF-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C=C1 IRZRJANZDIOOIF-GAJNKVMBSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- UOGHWGUWBMORBA-UHFFFAOYSA-N 2-[3-[(8-chloroquinolin-2-yl)amino]-2-methylphenoxy]ethanol Chemical compound CC1=C(C=CC=C1OCCO)NC2=NC3=C(C=CC=C3Cl)C=C2 UOGHWGUWBMORBA-UHFFFAOYSA-N 0.000 description 1
- NLGFJRUXCOHLGH-UHFFFAOYSA-N 2-[3-[(8-chloroquinolin-2-yl)amino]-4-methylphenoxy]ethanol Chemical compound CC1=C(C=C(C=C1)OCCO)NC2=NC3=C(C=CC=C3Cl)C=C2 NLGFJRUXCOHLGH-UHFFFAOYSA-N 0.000 description 1
- GAAWCDGFSMXODA-UHFFFAOYSA-N 2-[4-[(8-chloroquinolin-2-yl)amino]-3-methylphenoxy]ethanol Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(OCCO)C=C1)C GAAWCDGFSMXODA-UHFFFAOYSA-N 0.000 description 1
- VGSMGCCZWPTRAY-UHFFFAOYSA-N 2-[4-[(8-chloroquinolin-2-yl)amino]-3-propylphenoxy]ethanol Chemical compound C(CC1=CC(OCCO)=CC=C1NC1=NC2=C(C=CC=C2C=C1)Cl)C VGSMGCCZWPTRAY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VGYVBEJDXIPSDL-UHFFFAOYSA-N 2-bromo-4-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1Br VGYVBEJDXIPSDL-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SZYVPWPBRABKAB-UHFFFAOYSA-N 3-bromo-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(Br)=C1 SZYVPWPBRABKAB-UHFFFAOYSA-N 0.000 description 1
- HVGRRDZBMWNWSR-UHFFFAOYSA-N 3-fluoro-4-[3-methyl-4-(quinolin-2-ylamino)phenoxy]phenol Chemical compound FC=1C=C(C=CC=1OC1=CC(=C(C=C1)NC1=NC2=CC=CC=C2C=C1)C)O HVGRRDZBMWNWSR-UHFFFAOYSA-N 0.000 description 1
- OWKDVFIMQSAHFA-UHFFFAOYSA-N 4-cyclopentyloxy-2-methyl-1-nitrobenzene Chemical compound C1=C([N+]([O-])=O)C(C)=CC(OC2CCCC2)=C1 OWKDVFIMQSAHFA-UHFFFAOYSA-N 0.000 description 1
- JHFOWEGCZWLHNW-UHFFFAOYSA-N 4-fluoro-2-methyl-1-nitrobenzene Chemical compound CC1=CC(F)=CC=C1[N+]([O-])=O JHFOWEGCZWLHNW-UHFFFAOYSA-N 0.000 description 1
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 1
- OHSFXVFXNWTEKW-UHFFFAOYSA-N 8-chloro-N-(2,3-dimethyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C(=C(C=C1)OC(C)C)C)C OHSFXVFXNWTEKW-UHFFFAOYSA-N 0.000 description 1
- QCWDPINNHJJLEL-UHFFFAOYSA-N 8-chloro-N-(2,5-dimethyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C(=C1)C)OC(C)C)C QCWDPINNHJJLEL-UHFFFAOYSA-N 0.000 description 1
- STRZCDLAPHAUAO-UHFFFAOYSA-N 8-chloro-N-(2,6-dimethyl-4-phenoxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1C)OC1=CC=CC=C1)C STRZCDLAPHAUAO-UHFFFAOYSA-N 0.000 description 1
- SYZDPAJIGKYZQM-UHFFFAOYSA-N 8-chloro-N-(2,6-dimethyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1C)OC(C)C)C SYZDPAJIGKYZQM-UHFFFAOYSA-N 0.000 description 1
- HZIDPRZAZVXOTO-UHFFFAOYSA-N 8-chloro-N-(2-ethyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC(C)C)CC HZIDPRZAZVXOTO-UHFFFAOYSA-N 0.000 description 1
- YLWSGCJCPZNBSU-UHFFFAOYSA-N 8-chloro-N-(2-methyl-3-phenoxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C(=CC=C1)OC1=CC=CC=C1)C YLWSGCJCPZNBSU-UHFFFAOYSA-N 0.000 description 1
- WSJKVVQMWMPCPW-UHFFFAOYSA-N 8-chloro-N-(2-methyl-3-phenylmethoxyphenyl)quinolin-2-amine Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C=CC=1)NC1=NC2=C(C=CC=C2C=C1)Cl)C WSJKVVQMWMPCPW-UHFFFAOYSA-N 0.000 description 1
- QVTZFMDJMJTEFX-UHFFFAOYSA-N 8-chloro-N-(2-methyl-3-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C(=CC=C1)OC(C)C)C QVTZFMDJMJTEFX-UHFFFAOYSA-N 0.000 description 1
- AFLSPGUGRJEAPJ-UHFFFAOYSA-N 8-chloro-N-(2-methyl-4-naphthalen-1-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC1=CC=CC2=CC=CC=C12)C AFLSPGUGRJEAPJ-UHFFFAOYSA-N 0.000 description 1
- BHURZBKFPIUXRS-UHFFFAOYSA-N 8-chloro-N-(2-methyl-4-phenoxyphenyl)quinolin-2-amine 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.ClC=1C=CC=C2C=CC(=NC12)NC1=C(C=C(C=C1)OC1=CC=CC=C1)C BHURZBKFPIUXRS-UHFFFAOYSA-N 0.000 description 1
- YKEOPWPSNHBDGW-UHFFFAOYSA-N 8-chloro-N-(2-methyl-4-phenylmethoxyphenyl)quinolin-2-amine Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1)NC1=NC2=C(C=CC=C2C=C1)Cl)C YKEOPWPSNHBDGW-UHFFFAOYSA-N 0.000 description 1
- XFRFSVRCYGBYBL-UHFFFAOYSA-N 8-chloro-N-(2-methyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC(C)C)C XFRFSVRCYGBYBL-UHFFFAOYSA-N 0.000 description 1
- ILEDTUPOVJKZQW-UHFFFAOYSA-N 8-chloro-N-(2-methyl-5-phenoxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=CC(=C1)OC1=CC=CC=C1)C ILEDTUPOVJKZQW-UHFFFAOYSA-N 0.000 description 1
- RIJFRSNMXMECAW-UHFFFAOYSA-N 8-chloro-N-(2-methyl-5-propan-2-yl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C(=C1)C(C)C)OC(C)C)C RIJFRSNMXMECAW-UHFFFAOYSA-N 0.000 description 1
- GRDDPMUCWJSRNC-UHFFFAOYSA-N 8-chloro-N-(2-methyl-5-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=CC(=C1)OC(C)C)C GRDDPMUCWJSRNC-UHFFFAOYSA-N 0.000 description 1
- FHRMHAGDRJAGAA-UHFFFAOYSA-N 8-chloro-N-(3-phenoxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=CC(=CC=C1)OC1=CC=CC=C1 FHRMHAGDRJAGAA-UHFFFAOYSA-N 0.000 description 1
- OXRCOSWWIHYDCM-UHFFFAOYSA-N 8-chloro-N-(4-cyclobutyloxy-2-cyclopropylphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC1CCC1)C1CC1 OXRCOSWWIHYDCM-UHFFFAOYSA-N 0.000 description 1
- BLEMMTUGRGEHPE-UHFFFAOYSA-N 8-chloro-N-(4-cyclobutyloxy-2-ethylphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC1CCC1)CC BLEMMTUGRGEHPE-UHFFFAOYSA-N 0.000 description 1
- CSHBJGJKRGDAPP-UHFFFAOYSA-N 8-chloro-N-(4-cyclohexyloxy-2-methylphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC1CCCCC1)C CSHBJGJKRGDAPP-UHFFFAOYSA-N 0.000 description 1
- MYCHHXAUECBWIK-UHFFFAOYSA-N 8-chloro-N-(4-cyclopentyloxy-2-cyclopropylphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC1CCCC1)C1CC1 MYCHHXAUECBWIK-UHFFFAOYSA-N 0.000 description 1
- ONEWFZJGZAPHIX-UHFFFAOYSA-N 8-chloro-N-(4-cyclopentyloxy-2-methylphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC1CCCC1)C ONEWFZJGZAPHIX-UHFFFAOYSA-N 0.000 description 1
- FZPMMIXUALVLAP-UHFFFAOYSA-N 8-chloro-N-(4-ethoxy-2-methylphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OCC)C FZPMMIXUALVLAP-UHFFFAOYSA-N 0.000 description 1
- QAFPYEZLKJGCIB-UHFFFAOYSA-N 8-chloro-N-(4-methoxy-2-methylphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC)C QAFPYEZLKJGCIB-UHFFFAOYSA-N 0.000 description 1
- WWAXBDCGSFIHEK-UHFFFAOYSA-N 8-chloro-N-(4-phenoxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=CC=C(C=C1)OC1=CC=CC=C1 WWAXBDCGSFIHEK-UHFFFAOYSA-N 0.000 description 1
- CBXSLPAQDOTCHK-UHFFFAOYSA-N 8-chloro-N-(5-cyclopropyl-2-methyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C(=C1)C1CC1)OC(C)C)C CBXSLPAQDOTCHK-UHFFFAOYSA-N 0.000 description 1
- MJDMEELLHLIVCQ-UHFFFAOYSA-N 8-chloro-N-[2-(2-methylpropyl)-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC(F)(F)F)CC(C)C MJDMEELLHLIVCQ-UHFFFAOYSA-N 0.000 description 1
- VHLZJSCUHRTABC-UHFFFAOYSA-N 8-chloro-N-[2-cyclopropyl-6-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1C)OC(F)(F)F)C1CC1 VHLZJSCUHRTABC-UHFFFAOYSA-N 0.000 description 1
- RCNFFYYXRJPHEV-UHFFFAOYSA-N 8-chloro-N-[2-ethyl-6-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1C)OC(F)(F)F)CC RCNFFYYXRJPHEV-UHFFFAOYSA-N 0.000 description 1
- OGCDIVXIZCQOEK-UHFFFAOYSA-N 8-chloro-N-[2-methyl-3-(pyridin-3-ylmethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C(=CC=C1)OCC=1C=NC=CC=1)C OGCDIVXIZCQOEK-UHFFFAOYSA-N 0.000 description 1
- ZAQVFJORJRMTAG-UHFFFAOYSA-N 8-chloro-N-[2-methyl-4-(oxetan-3-yloxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC1COC1)C ZAQVFJORJRMTAG-UHFFFAOYSA-N 0.000 description 1
- CKIHRMZUXSGVEH-UHFFFAOYSA-N 8-chloro-N-[2-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OCC1=NC=CC=C1)C CKIHRMZUXSGVEH-UHFFFAOYSA-N 0.000 description 1
- QYXDLVQIGUMSIR-UHFFFAOYSA-N 8-chloro-N-[2-methyl-4-(pyridin-4-ylmethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OCC1=CC=NC=C1)C QYXDLVQIGUMSIR-UHFFFAOYSA-N 0.000 description 1
- AJEBDAVEULURQV-UHFFFAOYSA-N 8-chloro-N-[2-methyl-4-[2-(trifluoromethoxy)ethoxy]phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OCCOC(F)(F)F)C AJEBDAVEULURQV-UHFFFAOYSA-N 0.000 description 1
- HWSGNLPSGATTLF-UHFFFAOYSA-N 8-chloro-N-[2-methyl-6-propyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1CCC)OC(F)(F)F)C HWSGNLPSGATTLF-UHFFFAOYSA-N 0.000 description 1
- AADSUFCFQNGXIV-UHFFFAOYSA-N 8-chloro-N-[2-propyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=C(C=C(C=C1)OC(F)(F)F)CCC AADSUFCFQNGXIV-UHFFFAOYSA-N 0.000 description 1
- XUCLGPFNXCNFMD-UHFFFAOYSA-N 8-chloro-N-[4-(2-fluorophenoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=CC=C(C=C1)OC1=C(C=CC=C1)F XUCLGPFNXCNFMD-UHFFFAOYSA-N 0.000 description 1
- YBLDZHHCTWKBCU-UHFFFAOYSA-N 8-chloro-N-[4-(4-chlorophenoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=CC=C(C=C1)OC1=CC=C(C=C1)Cl YBLDZHHCTWKBCU-UHFFFAOYSA-N 0.000 description 1
- JEGMEVZVCXDJFU-UHFFFAOYSA-N 8-chloro-N-[4-(4-fluorophenoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=CC=C(C=C1)OC1=CC=C(C=C1)F JEGMEVZVCXDJFU-UHFFFAOYSA-N 0.000 description 1
- LNMKEBPPFBWQCA-UHFFFAOYSA-N 8-chloro-N-[4-(4-methylphenoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=CC=C(C=C1)OC1=CC=C(C=C1)C LNMKEBPPFBWQCA-UHFFFAOYSA-N 0.000 description 1
- DMGALOCEQNYOHP-UHFFFAOYSA-N 8-chloro-n-[2-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound CC1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 DMGALOCEQNYOHP-UHFFFAOYSA-N 0.000 description 1
- 208000007887 Alphavirus Infections Diseases 0.000 description 1
- 241000351313 Aquaparamyxovirus Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000035315 Avulavirus Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000710946 Barmah Forest virus Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000776207 Bornaviridae Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000004293 Chikungunya Fever Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000521069 Ferlavirus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000035314 Henipavirus Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- 241001559187 Human rubulavirus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000456230 Mymonaviridae Species 0.000 description 1
- AJPKJQYZBFPKFZ-UHFFFAOYSA-N N-(2,5-dimethyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound C(C)(C)OC1=CC(=C(C=C1C)NC1=NC2=CC=CC=C2C=C1)C AJPKJQYZBFPKFZ-UHFFFAOYSA-N 0.000 description 1
- IFQNSEYCMABLRM-UHFFFAOYSA-N N-(2,6-dimethyl-4-phenoxyphenyl)quinolin-2-amine Chemical compound CC1=C(C(=CC(=C1)OC1=CC=CC=C1)C)NC1=NC2=CC=CC=C2C=C1 IFQNSEYCMABLRM-UHFFFAOYSA-N 0.000 description 1
- JTTKZZKIZLTIJV-UHFFFAOYSA-N N-(2-cyclopropyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound C1(CC1)C1=C(C=CC(=C1)OC(C)C)NC1=NC2=CC=CC=C2C=C1 JTTKZZKIZLTIJV-UHFFFAOYSA-N 0.000 description 1
- QRFHCPGGXRIFQB-UHFFFAOYSA-N N-(2-ethyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound C(C)C1=C(C=CC(=C1)OC(C)C)NC1=NC2=CC=CC=C2C=C1 QRFHCPGGXRIFQB-UHFFFAOYSA-N 0.000 description 1
- KYFQPRPHQJJPEJ-UHFFFAOYSA-N N-(2-methyl-3-phenoxyphenyl)quinolin-2-amine Chemical compound CC1=C(C=CC=C1OC1=CC=CC=C1)NC1=NC2=CC=CC=C2C=C1 KYFQPRPHQJJPEJ-UHFFFAOYSA-N 0.000 description 1
- RJZSTDIKCANVKU-UHFFFAOYSA-N N-(2-methyl-4-phenoxyphenyl)quinolin-2-amine Chemical compound CC1=C(C=CC(=C1)OC1=CC=CC=C1)NC1=NC2=CC=CC=C2C=C1 RJZSTDIKCANVKU-UHFFFAOYSA-N 0.000 description 1
- INTMPEBPBXQDPG-UHFFFAOYSA-N N-(2-methyl-4-propan-2-yloxyphenyl)quinolin-2-amine Chemical compound C(C)(C)OC1=CC(=C(C=C1)NC1=NC2=CC=CC=C2C=C1)C INTMPEBPBXQDPG-UHFFFAOYSA-N 0.000 description 1
- JGTNFPDQYWYAOV-UHFFFAOYSA-N N-(4-propan-2-yloxy-2-propylphenyl)quinolin-2-amine Chemical compound C(C)(C)OC1=CC(=C(C=C1)NC1=NC2=CC=CC=C2C=C1)CCC JGTNFPDQYWYAOV-UHFFFAOYSA-N 0.000 description 1
- ZVHYBUGMNNSMEZ-UHFFFAOYSA-N N-[2-cyclopropyl-4-(2-fluoro-4-methoxyphenoxy)phenyl]quinolin-2-amine Chemical compound C1(CC1)C1=C(C=CC(=C1)OC1=C(C=C(C=C1)OC)F)NC1=NC2=CC=CC=C2C=C1 ZVHYBUGMNNSMEZ-UHFFFAOYSA-N 0.000 description 1
- WTLJZVGVDAEAGJ-UHFFFAOYSA-N N-[2-cyclopropyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1(CC1)C1=C(C=CC(=C1)OC(F)(F)F)NC1=NC2=CC=CC=C2C=C1 WTLJZVGVDAEAGJ-UHFFFAOYSA-N 0.000 description 1
- LZOPFHUWCIZLAW-UHFFFAOYSA-N N-[2-ethyl-4-(2-fluoro-4-methoxyphenoxy)phenyl]quinolin-2-amine Chemical compound C(C)C1=C(C=CC(=C1)OC1=C(C=C(C=C1)OC)F)NC1=NC2=CC=CC=C2C=C1 LZOPFHUWCIZLAW-UHFFFAOYSA-N 0.000 description 1
- CZDQRKBVNOUTBM-UHFFFAOYSA-N N-[2-ethyl-4-(2-fluorophenoxy)phenyl]quinolin-2-amine Chemical compound C(C)C1=C(C=CC(=C1)OC1=C(C=CC=C1)F)NC1=NC2=CC=CC=C2C=C1 CZDQRKBVNOUTBM-UHFFFAOYSA-N 0.000 description 1
- QJWSREUQGRCBMB-UHFFFAOYSA-N N-[2-ethyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C(C)C1=C(C=CC(=C1)OC(F)(F)F)NC1=NC2=CC=CC=C2C=C1 QJWSREUQGRCBMB-UHFFFAOYSA-N 0.000 description 1
- LXNJHXCIVMSAPR-UHFFFAOYSA-N N-[2-propyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C(CC)C1=C(C=CC(=C1)OC(F)(F)F)NC1=NC2=CC=CC=C2C=C1 LXNJHXCIVMSAPR-UHFFFAOYSA-N 0.000 description 1
- OVMUNVGVCXRZDU-UHFFFAOYSA-N N-[4-(2-fluoro-4-methoxyphenoxy)-2-methylphenyl]quinolin-2-amine Chemical compound FC1=C(OC2=CC(=C(C=C2)NC2=NC3=CC=CC=C3C=C2)C)C=CC(=C1)OC OVMUNVGVCXRZDU-UHFFFAOYSA-N 0.000 description 1
- KWJJQFRBEISMJJ-UHFFFAOYSA-N N-[4-(2-fluoro-4-methoxyphenoxy)phenyl]quinolin-2-amine Chemical compound FC1=C(OC2=CC=C(C=C2)NC2=NC3=CC=CC=C3C=C2)C=CC(=C1)OC KWJJQFRBEISMJJ-UHFFFAOYSA-N 0.000 description 1
- IUWIOJBVBXYYHD-UHFFFAOYSA-N N-[4-(2-fluorophenoxy)phenyl]quinolin-2-amine Chemical compound FC1=C(OC2=CC=C(C=C2)NC2=NC3=CC=CC=C3C=C2)C=CC=C1 IUWIOJBVBXYYHD-UHFFFAOYSA-N 0.000 description 1
- DWGZCMSOHQONBZ-UHFFFAOYSA-N N-[4-(4-chlorophenoxy)phenyl]quinolin-2-amine Chemical compound ClC1=CC=C(OC2=CC=C(C=C2)NC2=NC3=CC=CC=C3C=C2)C=C1 DWGZCMSOHQONBZ-UHFFFAOYSA-N 0.000 description 1
- PNIFQHHTMUBJRG-UHFFFAOYSA-N N-[4-(4-fluorophenoxy)phenyl]quinolin-2-amine Chemical compound FC1=CC=C(OC2=CC=C(C=C2)NC2=NC3=CC=CC=C3C=C2)C=C1 PNIFQHHTMUBJRG-UHFFFAOYSA-N 0.000 description 1
- ALRXNHRCFCMBDY-UHFFFAOYSA-N N-[4-(4-methoxyphenoxy)-2-methylphenyl]quinolin-2-amine Chemical compound COC1=CC=C(OC2=CC(=C(C=C2)NC2=NC3=CC=CC=C3C=C2)C)C=C1 ALRXNHRCFCMBDY-UHFFFAOYSA-N 0.000 description 1
- RBYDGNFTRLBNCC-UHFFFAOYSA-N N-[4-(4-methylphenoxy)phenyl]quinolin-2-amine Chemical compound C1(=CC=C(C=C1)OC1=CC=C(C=C1)NC1=NC2=CC=CC=C2C=C1)C RBYDGNFTRLBNCC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000439378 Nyamiviridae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000711502 Paramyxovirinae Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 208000004692 Pneumovirus Infections Diseases 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000982623 Quaranjavirus Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000489711 Sunviridae Species 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000868137 Tonate virus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000608278 Una virus Species 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- KXVUSQIDCZRUKF-UHFFFAOYSA-N bromocyclobutane Chemical compound BrC1CCC1 KXVUSQIDCZRUKF-UHFFFAOYSA-N 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- HRBOBRURGPUCSA-UHFFFAOYSA-N methyl 2-[4-(quinolin-2-ylamino)phenoxy]benzoate Chemical compound N1=C(C=CC2=CC=CC=C12)NC1=CC=C(OC2=C(C(=O)OC)C=CC=C2)C=C1 HRBOBRURGPUCSA-UHFFFAOYSA-N 0.000 description 1
- KPZVXTAHBSHFLC-UHFFFAOYSA-N methyl 2-[4-[(8-chloroquinolin-2-yl)amino]phenoxy]benzoate Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=CC=C(OC2=C(C(=O)OC)C=CC=C2)C=C1 KPZVXTAHBSHFLC-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- DFNDJRRFQJXVJE-UHFFFAOYSA-N n-(4-phenoxyphenyl)quinolin-2-amine Chemical compound C=1C=C2C=CC=CC2=NC=1NC(C=C1)=CC=C1OC1=CC=CC=C1 DFNDJRRFQJXVJE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305910.4A EP3594206A1 (en) | 2018-07-09 | 2018-07-09 | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP18305910.4 | 2018-07-09 | ||
| PCT/EP2019/068459 WO2020011810A1 (en) | 2018-07-09 | 2019-07-09 | Phenyl-n-quinoline derivatives for treating a rna virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021000331A2 true BR112021000331A2 (pt) | 2021-04-06 |
Family
ID=63035966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021000331-2A BR112021000331A2 (pt) | 2018-07-09 | 2019-07-09 | Derivados de fenil-n-quinolina para tratamento de uma infecção por vírus de rna |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US12084422B2 (https=) |
| EP (2) | EP3594206A1 (https=) |
| JP (2) | JP7504409B2 (https=) |
| KR (1) | KR102758510B1 (https=) |
| CN (1) | CN112566899B (https=) |
| AU (1) | AU2019300100B2 (https=) |
| BR (1) | BR112021000331A2 (https=) |
| CU (1) | CU24674B1 (https=) |
| MX (1) | MX2021000089A (https=) |
| WO (1) | WO2020011810A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| US20230142547A1 (en) | 2020-03-20 | 2023-05-11 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3884946A1 (en) | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3881844A1 (en) | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| IL326865A (en) * | 2023-08-30 | 2026-04-01 | Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd | Compound for regulating microRNA activity A-124 |
| WO2025149545A1 (en) * | 2024-01-11 | 2025-07-17 | F. Hoffmann-La Roche Ag | Heteroarylphenyl ether derivatives |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| FR2830862A1 (fr) | 2001-10-16 | 2003-04-18 | Lipha | Derives nitroso de la diphenylamine a fonction ether ou thioether, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| DE602004020073D1 (de) | 2003-08-21 | 2009-04-30 | Osi Pharm Inc | 3-substituierte imidazopyridinderivate als c-kit-inhibitoren |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| EP1697343B1 (en) | 2003-12-18 | 2009-07-01 | Tibotec Pharmaceuticals Ltd. | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication |
| FR2866647B1 (fr) * | 2004-02-20 | 2006-10-27 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2006037117A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ES2574670T3 (es) | 2005-03-17 | 2016-06-21 | Janssen Sciences Ireland Uc | 1,3-Dihidro-bencimidazol-2-ilidenoaminas como inhibidores de replicación del virus sincicial respiratorio |
| US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| ATE475660T1 (de) | 2005-12-21 | 2010-08-15 | Abbott Lab | Antivirale verbindungen |
| US7915411B2 (en) | 2005-12-21 | 2011-03-29 | Abbott Laboratories | Anti-viral compounds |
| FR2901273B1 (fr) | 2006-05-19 | 2010-12-24 | Anaconda Pharma | Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| US20140187641A1 (en) | 2012-08-23 | 2014-07-03 | Gtx | Estrogen receptor ligands and methods of use thereof |
| SI2440547T1 (sl) | 2009-06-12 | 2023-05-31 | Abivax | Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju |
| JP2011026251A (ja) * | 2009-07-27 | 2011-02-10 | Kowa Co | ２−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤 |
| US8846713B2 (en) | 2010-06-24 | 2014-09-30 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2505198A1 (en) | 2011-04-01 | 2012-10-03 | Société Splicos | Compounds for use as therapeutic agents affecting p53 expression and/or activity |
| WO2014164667A1 (en) | 2013-03-11 | 2014-10-09 | Georgetown University | Dengue and west nile virus protease inhibitors |
| CA2916623C (en) * | 2013-07-05 | 2021-09-14 | Abivax | Bicyclic compounds useful for treating diseases caused by retroviruses |
| RU2628800C2 (ru) | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| US20160143884A1 (en) | 2014-11-26 | 2016-05-26 | Esanex, Inc. | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) |
| EP3059591A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| PT3429998T (pt) | 2016-03-18 | 2021-11-04 | Prosynergia S A R L | Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais |
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
-
2018
- 2018-07-09 EP EP18305910.4A patent/EP3594206A1/en not_active Ceased
-
2019
- 2019-07-09 US US17/259,364 patent/US12084422B2/en active Active
- 2019-07-09 MX MX2021000089A patent/MX2021000089A/es unknown
- 2019-07-09 KR KR1020217001298A patent/KR102758510B1/ko active Active
- 2019-07-09 CU CU2021000006A patent/CU24674B1/es unknown
- 2019-07-09 BR BR112021000331-2A patent/BR112021000331A2/pt unknown
- 2019-07-09 JP JP2021500215A patent/JP7504409B2/ja active Active
- 2019-07-09 WO PCT/EP2019/068459 patent/WO2020011810A1/en not_active Ceased
- 2019-07-09 AU AU2019300100A patent/AU2019300100B2/en active Active
- 2019-07-09 CN CN201980045917.4A patent/CN112566899B/zh active Active
- 2019-07-09 EP EP19737536.3A patent/EP3820852A1/en active Pending
-
2023
- 2023-10-17 JP JP2023179000A patent/JP7673362B2/ja active Active
-
2024
- 2024-05-10 US US18/660,578 patent/US12479802B2/en active Active
-
2025
- 2025-10-15 US US19/359,300 patent/US20260035348A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7673362B2 (ja) | 2025-05-09 |
| US20260035348A1 (en) | 2026-02-05 |
| US12084422B2 (en) | 2024-09-10 |
| KR20210052432A (ko) | 2021-05-10 |
| CA3103867A1 (en) | 2020-01-16 |
| US20240308964A1 (en) | 2024-09-19 |
| US20210309611A1 (en) | 2021-10-07 |
| MX2021000089A (es) | 2021-03-25 |
| US12479802B2 (en) | 2025-11-25 |
| EP3820852A1 (en) | 2021-05-19 |
| CU24674B1 (es) | 2023-08-08 |
| EP3594206A1 (en) | 2020-01-15 |
| WO2020011810A1 (en) | 2020-01-16 |
| JP7504409B2 (ja) | 2024-06-24 |
| AU2019300100A1 (en) | 2021-01-21 |
| AU2019300100B2 (en) | 2024-10-24 |
| CN112566899B (zh) | 2024-01-30 |
| CU20210006A7 (es) | 2021-08-06 |
| JP2024053563A (ja) | 2024-04-15 |
| JP2021524481A (ja) | 2021-09-13 |
| KR102758510B1 (ko) | 2025-01-22 |
| CN112566899A (zh) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021000331A2 (pt) | Derivados de fenil-n-quinolina para tratamento de uma infecção por vírus de rna | |
| ES2965067T3 (es) | Derivados de fenil/piridil-NH-fenil/piridilo para una tratar infección por virus de ARN | |
| RU2805064C2 (ru) | Производные фенил-n-хинолина для лечения рнк-вирусной инфекции | |
| CA3103867C (en) | Phenyl-n-quinoline derivatives for treating an rna virus infection | |
| HK40040036A (en) | Phenyl-n-quinoline derivatives for treating a rna virus infection | |
| HK40040036B (zh) | 用於治疗rna病毒感染的苯基-n-喹啉衍生物 | |
| RU2815493C2 (ru) | Арил-n-арильные производные для лечения рнк-вирусной инфекции | |
| HK40039623A (en) | Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating rna virus infection | |
| HK40039623B (zh) | 用於治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |